Judge pares down sales rep gender suit against Allergan's Forest unit; Teva tax incentives targeted in Israeli report;

@FiercePharma: U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: Here's the latest episode of @FierceBiotech radio--and it even comes endorsed by @brentlsaunders! (He's real.) Listen | Follow @CarlyHFierce

> A federal judge narrowed a $100 million gender discrimination lawsuit against Allergan's ($AGN) Forest Laboratories unit, saying many of the claims from female sales reps may be time-barred. Report

> An Israeli government committee said Teva Pharmaceutical ($TEVA) enjoyed a third of the state's tax incentives from 2005 to 2010, while delivering just 1% of the nation's industrial jobs; the company pointed out that accounts for 1.5% of the country's GDP. Report

> Allergan's Actavis unit is recalling 26 lots of its Lutera contraceptive pills after learning they were distributed with outdated package inserts. Report

> The Finnish pharmaceutical company Orion hiked its 2015 profit forecast after stronger-than-expected performance in the first half. Report

> Teva Pharmaceutical rolled out its version of the migraine drug Axert (almotriptan malate), with exclusive generic rights through Nov. 7. Release | Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Brain scan can be used to distinguish between traumatic brain injury and PTSD. Article | Follow @FierceMedDev

@EmilyWFierce: Sunshine Act payment data leaves out newly influential prescribers. More from FiercePharma | Follow @EmilyWFierce

> One year after IPO, Intersect ENT still going strong--starts pivotal testing, raises $103M. Story

> Not quite profitable, IPO star K2M cashes out investors with $177M in 2015. Report

Biotech News

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Female libido drug lobbying sparks a backlash as FDA decision looms. Story | Follow @JohnCFierce

@DamianFierce: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Press release | Follow @DamianFierce

> Back-to-back PhII flops for lead drug scuttles Aquinox stock. More

> J&J's IL-23 psoriasis contender scores a PhIIb win in a turbulent race. Article

> Celgene recommits to Epizyme, adding $620M in cancer drug bonuses. Report

Vaccines News

> Shantha's cholera jab prevents 37% of cholera cases in Bangladeshi study. More

> Poll: parents view vaccines as safer, more beneficial. Item

> J&J's HIV vaccine shows promise in monkeys; PhI/IIa to start soon. Article

> NIAID launches PhI trial of investigational West Nile virus vaccine. Story

> U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. Report

CRO News

> Recipharm takes a 25% stake in its drug-developing partner. Item

> Parexel uses virtual clinical trials to improve real-life R&D. Report

> Charles River spends $212M to beef up its microbial testing. Story

> BioClinica buys a patient recruitment firm to bolster study startup. Article

Pharma Manufacturing News

> Twitter chat redux: In case you missed the chat, we don't want you to miss the info. More

> India may use FDA as model for bolstering its oversight. Item

> Lupin antibiotic products banned by Brazil. Story

> Chinese staffer key to negotiating deal to bolster FDA staff in China. Report

> FDA sends drugmakers warning letters reminding them to pay up. Article

Pharma Asia News

> India's Lupin hit by Brazil regulator suspension of antibiotic API. News

> Drug firms in Australia to report gifts to doctors starting Oct. 1, ABC says. Item

> India aims at U.S. FDA standards on drugs with name change afoot. Report

> Watch out AbbVie, Samsung Bioepis does fine with Humira biosimilar in PhIII. Story

> Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou. Article

And Finally... Three clusters of counties in the U.S. have "unnecessarily high" death rates from colon cancer. Report